By Dean Seal
Edwards Lifesciences had a higher profit and sales in its fourth quarter as demand for its products held strong.
The medical-technology company posted a profit of $385.6 million, or 65 cents a share, up from $369.9 million, or 61 cents a share, in the same quarter a year ago.
Stripping out one-time items, adjusted earnings were 59 cents a share. Analysts polled by Factset had been expecting 55 cents a share.
Sales jumped 9% to $1.39 billion, topping analyst projections for $1.36 billion, according to FactSet.
The Irvine, Calif., company said the top-line growth was driven by strong demand for its transcatheter aortic valve replacements and repair and replacement technologies for both mitral and tricuspid valves.
For the first quarter of 2025, the company expects adjusted earnings of 58 cents to 64 cents a share on $1.35 billion to $1.43 billion in revenue. That's in line with analyst views for adjusted earnings of 59 cents a share on $1.41 billion in revenue.
The stock rose 6.7% to $75.69 in postmarket trading.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
February 11, 2025 17:07 ET (22:07 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.